Generation and analysis of vaccinia virus recombinants.
Mazzara
G P
GP
Therion Biologics Corporation, Cambridge, Massachusetts 02142.
Destree
A
A
Mahr
A
A
D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D004261:DNA Replication; D004274:DNA, Recombinant / Q000378:metabolism; D015686:Gene Products, env / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D005822:Genetic Vectors; D015699:HIV Envelope Protein gp120 / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D010957:Plasmids; D011401:Promoter Regions, Genetic; D011498:Protein Precursors / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011995:Recombination, Genetic; D015183:Restriction Mapping; D013728:Terminator Regions, Genetic; D014158:Transcription, Genetic; D014162:Transfection / Q000379:methods*; D014616:Vaccinia virus / Q000235:genetics* / Q000254:growth & development
D004274:DNA, Recombinant; D015686:Gene Products, env; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D012333:RNA, Messenger